lunes, 24 de junio de 2024

FDA grants accelerated approval to adagrasib with cetuximab for KRAS G12C-mutated colorectal cancer

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-adagrasib-cetuximab-kras-g12c-mutated-colorectal-cancer

No hay comentarios: